Cancer Cell 2004, 6:387–398.PubMedCrossRef Epigenetics inhibitor 17. van Dartel M, Cornelissen PWA, Redeker

S, Tarkkanen M, Knuutila S, Hogendoorn PCW, Wsterveld A, Gomes I, Bras J, Hulsebos TJM: Amplification of 17p11.2-p12, including PMP22, TOP3A and MAPK7 in high-grade osteosarcoma. Cancer Genet Cytogenet 2002, 139:91–96.PubMedCrossRef 18. van Dartel M, Redeker S, Bras J, Kool M, Hulsebos TJM: Lenvatinib overexpression through amplification of genes in chromosome region 17p11.2-p12 in high-grade osteosarcoma. Cancer Genet Cytogenet 2004, 152:8–14.PubMedCrossRef 19. van Dartel M, Hulsebos TJM: Amplification and overexpression of genes in 17p11.2-p12 in osteosarcoma. Cancer Genet Cytogenet 2004, 153:77–80.PubMedCrossRef 20. Henriksen J, Aagesen TH, Maelandsmo GM, Lothe RA, Myklebost

O, Forus A: Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation. Oncogene 2003, 22:5358–5361.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions MK participated in the data collection, performed the statistical analysis and drafted the manuscript. AS, TY and TH made substantial contributions to the analysis and interpretation of data. KS helped to draft the manuscript. All authors read and approved the final manuscript.”
“Background Lung cancer is the leading cause of cancer death in males and the second-leading cause of cancer deaths in females worldwide check details [1]. In the past decades, lung adenocarcinoma,

one histological subtype of non-small cell lung cancer (NSCLC), has become the most common histologic type among all lung cancers diagnosed [2]. Platinum based combination chemotherapy is the standard chemotherapy for NSCLC, and cisplatin is widely used for the treatment of lung cancer [3]. However, individuals Demeclocycline respond to chemotherapy differently and the efficacy of cisplatin treatment is often impaired by the emergence of resistance to this drug [4]. Therefore, elucidating the mechanism underlying the development of chemoresistance would promote our understanding of lung cancer progression and treatment failure. The heterodimeric Ku antigen, which acts as a molecular detector of DNA double strands, consists of two subunits of 70 kDa (Ku70) and 80 kDa (Ku80 or Ku86) and activate DNA protein kinase (DNA-PK) by binding directly to free DNA termini in a non-sequence-specific manner [5, 6]. Expression of Ku was shown to be upregulated in human aggressive breast cancer, lung cancer and bladder cancer [7–10]. Moreover, Ku is involved in the resistance of ovarian cancer and leukemic cells to cisplatin [11–13]. However, little is known about the expression of Ku80 and its role in cisplatin resistance in human lung adenocarcinoma.